Enzo Biochem’s Clinical Labs unit is collaborating with Italy-based DiaSorin, a global provider of biotechnologies, which will enable the lab to provide physician-clients in metropolitan New York with advanced diagnostic tools and will also serve to evaluate new DiaSorin offerings in the future.
“The LIAISON XL, with its expanded menu, will offer specialty testing, included infectious disease, growth, hypertension and bone and mineral,” said Barry Weiner, Enzo president.
Enzo Clinical Labs has added two new DiaSorin LIAISON XL Analyzers, a new high throughput, chemiluminescent, random access analyzer that provides a menu of over 30 assays. The system requires no daily maintenance with most tests and can manage up to 25 different assays on board.
Enzo Labs initially will offer a number of DiaSorin LIAISON XL tests to its customers, including the LIAISON 25 OH Vitamin D TOTAL assay, which measures both 25-OH D2 and 25-OH D3 metabolites to accurately assess Vitamin D sufficiency. Enzo also will offer DiaSorin’s CMV IgM and Borrelia burgdorferi assays. These tests are the only fully automated, FDA cleared, chemiluminescent assays available for the diagnosis and treatment of certain types of hypertension and primary aldosteronism.
